Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Milberg, Oleg [1 ]
Chiu, Joannellyn [1 ]
Hazra, Anasuya [1 ]
Upadhyay, Sameer [1 ]
Kroog, Glenn S. [1 ]
Lorenc, Karen Rodriguez [1 ]
Davis, John D. [1 ]
Dicioccio, A. Thomas [1 ]
Harnisch, Lutz O. [1 ]
Chittenden, Jason [1 ]
机构：
[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-200109
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7056 / 7057
页数：2
相关论文
共 50 条
  • [41] Population pharmacokinetics and exposure-response analyses for efficacy and safety of apadacitinib in patients with axial Spondyloarthritis
    Bhatnagar, Sumit
    Eckert, Doerthe
    Stodtmann, Sven
    Song, In-Ho
    Wung, Peter
    Liu, Wei
    Mohamed, Mohamed-Eslam F.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (02):
  • [42] Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Mercier, Francois
    Djebli, Nassim
    Gonzalez-Sales, Mario
    Jaminion, Felix
    Meneses-Lorente, Georgina
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 363 - 372
  • [43] Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients
    Zhou, Diansong
    Li, Jianguo
    Learoyd, Maria
    Bui, Khanh
    Berges, Alienor
    Milenkova, Tsveta
    Al-Huniti, Nidal
    Tomkinson, Helen
    Xu, Hongmei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1492 - 1500
  • [44] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1
    Suvannasankha, Attaya
    Lee, Hans
    Bumma, Naresh
    Dhodapkar, Madhav V.
    Richter, Joshua
    Hoffman, James E.
    Shah, Mansi
    Lentzsch, Suzanne
    Zonder, Jeffrey
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Wu, Ka Lung
    Pianko, Matthew
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Martinez Lopez, Joaquin
    DeVeaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Kroog, Glenn S.
    Houvras, Yariv
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S90 - S91
  • [46] A NOVEL CLINICAL UTILITY ANALYSIS COMBINING MULTIPLE EFFICACY AND SAFETY ENDPOINTS TO SUPPORT DOSE SELECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Huang, J.
    Balasubrahmanyam, B.
    Riggs, M. M.
    Baron, K. T.
    Gastonguay, M. R.
    Bloom, B. J.
    Kinnman, N.
    Zhang, Y.
    Hoock, T.
    Shen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S64 - S64
  • [47] Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)
    Boyapati, Anita
    Richter, Joshua
    Suvannasankha, Attaya
    Lee, Hans
    Chio, Erica
    Houvras, Yariv
    Singh, Nikhil
    Liang, Tao
    Chen, Jihua
    Hazra, Anasuya
    Zhu, Yuan
    Noguera-Troise, Irene
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S35 - S35
  • [48] Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
    Neeraj Gupta
    Richard Labotka
    Guohui Liu
    Ai-Min Hui
    Karthik Venkatakrishnan
    Investigational New Drugs, 2016, 34 : 338 - 346
  • [49] Bayesian sparse regression for exposure-response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma
    Fukae, Masato
    Rogers, James
    Garcia, Ramon
    Tachibana, Masaya
    Shimizu, Takako
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (10): : 1655 - 1669
  • [50] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
12345